Hubei Jumpcan Pharmaceutical Co., Ltd. (SHA: 600566)
China
· Delayed Price · Currency is CNY 27.54
-0.77 (-2.72%)
Sep 6, 2024, 3:00 PM CST
Hubei Jumpcan Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 2,821 | 2,823 | 2,171 | 1,719 | 1,277 | 1,623 | Upgrade
|
| Depreciation & Amortization | 295.08 | 298.26 | 308.8 | 293.81 | 280.95 | 232.5 | Upgrade
|
| Other Amortization | 7.23 | 6.46 | 9.49 | 10.25 | 7.12 | 2.54 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.03 | -0.13 | -5.22 | -0.65 | -3.35 | -0.3 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.95 | 1.09 | 0.53 | 0.42 | 0.77 | 1.96 | Upgrade
|
| Loss (Gain) From Sale of Investments | -91.89 | -96.33 | -58.89 | -161.53 | -22.31 | -22.31 | Upgrade
|
| Provision & Write-off of Bad Debts | -16.3 | -3.04 | 36.02 | 8.28 | 6.23 | 0.29 | Upgrade
|
| Other Operating Activities | 31.78 | 21.68 | 31.75 | 32.77 | 33.05 | 30.74 | Upgrade
|
| Change in Accounts Receivable | 196.61 | 22.81 | -713.7 | -181.19 | 15.25 | 28.72 | Upgrade
|
| Change in Inventory | -166.47 | -98.6 | -15.89 | -97.17 | 60.05 | -20.31 | Upgrade
|
| Change in Accounts Payable | -258.87 | 476.51 | 856.54 | 269.44 | 89.94 | 250.99 | Upgrade
|
| Change in Other Net Operating Assets | 9.36 | 8.52 | -4.07 | -6.24 | 31.16 | -2.26 | Upgrade
|
| Operating Cash Flow | 2,833 | 3,464 | 2,621 | 1,894 | 1,782 | 2,148 | Upgrade
|
| Operating Cash Flow Growth | -15.54% | 32.17% | 38.35% | 6.32% | -17.04% | 25.66% | Upgrade
|
| Capital Expenditures | -280.63 | -301.64 | -243.66 | -248.32 | -429.63 | -546.44 | Upgrade
|
| Sale of Property, Plant & Equipment | 1.25 | 7.98 | 52.82 | 0.79 | 1.54 | 0.68 | Upgrade
|
| Divestitures | - | - | - | - | 35.5 | - | Upgrade
|
| Investment in Securities | -3,602 | -182.68 | -1,380 | -474.89 | -1,096 | 89 | Upgrade
|
| Other Investing Activities | 48.55 | 82.12 | 67.53 | 49.11 | 7.6 | 12.31 | Upgrade
|
| Investing Cash Flow | -3,832 | -394.23 | -1,503 | -673.3 | -1,481 | -444.46 | Upgrade
|
| Short-Term Debt Issued | - | 1,095 | 400 | - | - | - | Upgrade
|
| Total Debt Issued | 1,518 | 1,095 | 400 | - | - | - | Upgrade
|
| Short-Term Debt Repaid | - | -400 | -7.52 | -0 | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -1.48 | -1.79 | -1.82 | -0 | -0 | Upgrade
|
| Total Debt Repaid | -552.97 | -401.48 | -9.31 | -1.82 | -0 | -0 | Upgrade
|
| Net Debt Issued (Repaid) | 964.62 | 693.96 | 390.69 | -1.82 | -0 | -0 | Upgrade
|
| Issuance of Common Stock | 18.68 | 14.21 | 97.18 | 50 | 1,405 | - | Upgrade
|
| Repurchase of Common Stock | -45.7 | -35.67 | - | - | - | - | Upgrade
|
| Common Dividends Paid | -1,705 | -823.19 | -605.45 | -409.37 | -1,009 | -1,005 | Upgrade
|
| Other Financing Activities | - | - | - | - | -22.41 | - | Upgrade
|
| Financing Cash Flow | -767.57 | -150.69 | -117.58 | -361.19 | 373.8 | -1,005 | Upgrade
|
| Net Cash Flow | -1,767 | 2,919 | 999.94 | 859.84 | 674.34 | 697.91 | Upgrade
|
| Free Cash Flow | 2,552 | 3,162 | 2,377 | 1,646 | 1,352 | 1,601 | Upgrade
|
| Free Cash Flow Growth | -17.78% | 33.03% | 44.42% | 21.74% | -15.56% | 53.80% | Upgrade
|
| Free Cash Flow Margin | 28.17% | 32.75% | 26.42% | 21.57% | 21.93% | 23.07% | Upgrade
|
| Free Cash Flow Per Share | 2.78 | 3.45 | 2.62 | 1.83 | 1.62 | 1.96 | Upgrade
|
| Cash Income Tax Paid | 1,604 | 1,650 | 1,264 | 1,177 | 926.3 | 1,090 | Upgrade
|
| Levered Free Cash Flow | 1,178 | 2,278 | 1,640 | 1,012 | 908.93 | 1,302 | Upgrade
|
| Unlevered Free Cash Flow | 1,195 | 2,289 | 1,659 | 1,034 | 929.58 | 1,321 | Upgrade
|
| Change in Net Working Capital | 553.21 | -470.31 | -170.92 | 65.76 | -205.39 | -506.2 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.